SCHEMBL2120607

SCHEMBL2120607

Cc1ccc(-c2cccs2)cc1N(C)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
LMNA P02545 4/20 0.44
MCOLN3 Q8TDD5 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP2C9 P11712 2/20 0.40
C5AR1 P21730 2/20 0.40
PIK3CD O00329 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
ACLY P53396 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118381 0.88 HSD17B1 (0.43) LMNACYP2C9C5AR1CA12CA1
SCHEMBL2122135 0.88 LMNA (0.41) LMNACYP2C9C5AR1PIK3CDCA12
SCHEMBL2118160 0.81 CYP2E1 (0.45) LMNACYP2C9PIK3CDKDM4EALDH1A1
SCHEMBL2117722 0.80 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2118249 0.76 PSEN1 (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2119380 0.76 LMNA (0.39) LMNASMN1; SMN2CYP2C9ALDH1A1MAPT
SCHEMBL17174229 0.75 C5AR1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2119022 0.75 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2117751 0.75 GHSR (0.58) SMN1; SMN2ALDH1A1ACLYGHSRMAPT
SCHEMBL7053207 0.74 KDM4E (0.50) LMNASMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 PSEN1 1316/4885PSEN2 2029/4885APH1B 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.